A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms MOAnab1
- 27 Mar 2017 Status changed from recruiting to completed.
- 08 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 08 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.